Department of Biology, Center for Biotechnology and Interdisciplinary Studies, Rensselaer, Polytechnic Institute, Troy, NY, USA.
Biotechnol Bioeng. 2013 May;110(5):1255-71. doi: 10.1002/bit.24841. Epub 2013 Feb 4.
Chinese hamster ovarian cells (CHO) cells have been extensively utilized for industrial production of biopharmaceutical products, such as monoclonal antibodies, human growth hormones, cytokines, and blood-products. Recent advances in recombinant DNA technology have resulted in the bioengineering of CHO cells that have robust gene amplification systems and can also be adapted to grow in suspension cultures. In parallel, recent advances in techniques and tools for decoding the CHO cell genome, transcriptome, proteome, and glycome have led to new areas of study for better understanding the metabolic pathways in CHO cells with the long-term goal of developing new biologics. This review paper discusses the recent advances in bioengineering strategies in CHO cell lines and the impact of the knowledge gained by CHO cell genomics, transcriptomics, and glycomics on the future of CHO-cell engineering.
中国仓鼠卵巢细胞(CHO)已被广泛用于生物制药产品的工业生产,如单克隆抗体、人生长激素、细胞因子和血液制品。重组 DNA 技术的最新进展导致 CHO 细胞的生物工程化,这些细胞具有强大的基因扩增系统,并且可以适应悬浮培养。同时,CHO 细胞基因组、转录组、蛋白质组和糖组解码技术和工具的最新进展也为更好地了解 CHO 细胞的代谢途径开辟了新的研究领域,长期目标是开发新的生物制剂。本文综述了 CHO 细胞系的生物工程策略的最新进展,以及通过 CHO 细胞基因组学、转录组学和糖组学获得的知识对 CHO 细胞工程未来的影响。